Arbutus, joined by Swiss licensee Genevant Sciences GmbH in filing the suit, claimed that the Pfizer-BioNTech Covid-19 vaccine infringed five different patents for lipid nanoparticle technologies, or LNP.
The lawsuit is the latest in a series of recent legal bouts between drug companies over the delivery-mechanism technology for the Covid-19 vaccine.
The LNP technology helped overcome a decades-long scientific problem over how to effectively deliver a vaccine’s ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
